Cargando…
Sipuleucel-T: immunotherapy for advanced prostate cancer
Prostate cancer continues to be one of the most serious afflictions of men of advanced age, remaining the most commonly diagnosed and second leading cause of cancer-related deaths in American men. The treatment options for patients with incurable metastatic, castrate-resistant disease have long focu...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818937/ https://www.ncbi.nlm.nih.gov/pubmed/24198636 http://dx.doi.org/10.2147/OAJU.S13069 |
_version_ | 1782289927991459840 |
---|---|
author | Olson, Brian M McNeel, Douglas G |
author_facet | Olson, Brian M McNeel, Douglas G |
author_sort | Olson, Brian M |
collection | PubMed |
description | Prostate cancer continues to be one of the most serious afflictions of men of advanced age, remaining the most commonly diagnosed and second leading cause of cancer-related deaths in American men. The treatment options for patients with incurable metastatic, castrate-resistant disease have long focused on various chemotherapeutic approaches, which provide a slight survival benefit while being associated with potentially significant side effects. However, the recent approval of sipuleucel-T has given patients with advanced disease an additional treatment option that has demonstrated benefit without the side effects associated with chemotherapy. Sipuleucel-T is an antigen-presenting cell-based active immunotherapy that utilizes a patient’s own immune cells, presumably to activate an antigen-specific immune response against tumor cells. This review focuses on the development and implementation of sipuleucel-T as a therapy for prostate cancer. Specifically, we present some of the issues associated with the management of advanced prostate cancer, the research and development that led to the approval of sipuleucel-T, how the approval of sipuleucel-T could change the clinical management of prostate cancer, and current and future areas of investigation that are being pursued with regard to sipuleucel-T and other treatments for advanced prostate cancer. |
format | Online Article Text |
id | pubmed-3818937 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-38189372013-11-06 Sipuleucel-T: immunotherapy for advanced prostate cancer Olson, Brian M McNeel, Douglas G Open Access J Urol Review Prostate cancer continues to be one of the most serious afflictions of men of advanced age, remaining the most commonly diagnosed and second leading cause of cancer-related deaths in American men. The treatment options for patients with incurable metastatic, castrate-resistant disease have long focused on various chemotherapeutic approaches, which provide a slight survival benefit while being associated with potentially significant side effects. However, the recent approval of sipuleucel-T has given patients with advanced disease an additional treatment option that has demonstrated benefit without the side effects associated with chemotherapy. Sipuleucel-T is an antigen-presenting cell-based active immunotherapy that utilizes a patient’s own immune cells, presumably to activate an antigen-specific immune response against tumor cells. This review focuses on the development and implementation of sipuleucel-T as a therapy for prostate cancer. Specifically, we present some of the issues associated with the management of advanced prostate cancer, the research and development that led to the approval of sipuleucel-T, how the approval of sipuleucel-T could change the clinical management of prostate cancer, and current and future areas of investigation that are being pursued with regard to sipuleucel-T and other treatments for advanced prostate cancer. Dove Medical Press 2011-05-03 /pmc/articles/PMC3818937/ /pubmed/24198636 http://dx.doi.org/10.2147/OAJU.S13069 Text en © 2011 Olson and McNeel, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Olson, Brian M McNeel, Douglas G Sipuleucel-T: immunotherapy for advanced prostate cancer |
title | Sipuleucel-T: immunotherapy for advanced prostate cancer |
title_full | Sipuleucel-T: immunotherapy for advanced prostate cancer |
title_fullStr | Sipuleucel-T: immunotherapy for advanced prostate cancer |
title_full_unstemmed | Sipuleucel-T: immunotherapy for advanced prostate cancer |
title_short | Sipuleucel-T: immunotherapy for advanced prostate cancer |
title_sort | sipuleucel-t: immunotherapy for advanced prostate cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818937/ https://www.ncbi.nlm.nih.gov/pubmed/24198636 http://dx.doi.org/10.2147/OAJU.S13069 |
work_keys_str_mv | AT olsonbrianm sipuleuceltimmunotherapyforadvancedprostatecancer AT mcneeldouglasg sipuleuceltimmunotherapyforadvancedprostatecancer |